

Jelmyto

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:	
Patient's ID:		Patient's Date of Birth:	
Physician's Name:		·	
Specialty:		NPI#:	
Physician Office Telephone:		Physician Office Fax:	
Referring Provider Info: ☐ Same as Re	equesting Provi	der	
Name:		NPI#:	
Fax:		Phone:	
Rendering Provider Info: ☐ Same as R	eferring Provid	er 🗆 Same as Requesting Provider	
Name:		NPI#:	
Fax:		Phone:	
		s in accordance with FDA-approved labeling, vidence-based practice guidelines.	
Patient Weight:	kg		
Patient Height:	cm		
Please indicate the place of service for the	e requested drug	:	
☐ Ambulatory Surgical	□ Home	Off Campus Outpatient Hospital	
☐ On Campus Outpatient Hospital	□ Office	☐ Pharmacv	

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Jelmyto SGM – 06/2022.

<u>Cli</u> 1.	what is the diagnosis? Upper tract urothelial cancer Other		
2.	What is the ICD-10 code?		
3.	Has the patient completed the initiation of the requested drug? ☐ Yes ☐ No If No, skip to #6		
4.	Has the patient achieved a complete response (as defined as a complete absence of tumor lesions by urine cytology and ureteroscopy) at 3 months after the initiation of the requested drug? <i>ACTION REQUIRED: If Yes, attach urine cytology and ureteroscopy report.</i> \square Yes \square No		
5.	Will the patient receive greater than 11 additional doses for continuation of therapy? ☐ Yes ☐ No No further questions		
6.	Is the disease non-metastatic, low-grade, low volume (5-15 mm)? ☐ Yes ☐ No		
7.	How will the requested drug be administered? ☐ Pyelocalyceal administration ☐ Other		
8.	Will the patient receive greater than 6 doses for the initiation of treatment? ☐ Yes ☐ No		
9.	Will the requested drug be administered once weekly for the first six weeks for initiation of therapy? ☐ Yes ☐ No		
	ttest that this information is accurate and true, and that documentation supporting this formation is available for review if requested by CVS Caremark or the benefit plan sponsor.		
X_			

Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Jelmyto SGM - 06/2022

Prescriber or Authorized Signature